Tumor Cell
Osteoblast (Bone Forming)
Osteoclast (Bone Resorbing)
Trabecular Bone Matrix
Radium-223 Alpha Track
Bone Mineral Density
84.2%
Structural Integrity
Tumor Burden
142
Cells in Lesion
Resorption / Formation
0.85
OC / OB Balance Ratio
Nociceptive Pain Index
3.4 / 10
Periosteal Stretch
Radium-223 Dose
55 kBq/kg
Alpha Emitter Target
The Metastatic 'Vicious Cycle' Mechanics:
Prostate cancer bone metastases secrete osteoblast-stimulating factors (such as ET-1 and BMPs) alongside osteoclast activators (RANKL and PTHrP). As osteoclasts resorb bone mineral, trapped growth factors like TGF-β are released, further driving prostate cancer proliferation.
Targeted Dual Therapy: Denosumab blocks RANKL to suppress pathological osteoclast activity, while Radium-223 (a calcium-mimetic alpha radiopharmaceutical) selectively targets high-turnover osteoblastic bone matrix, firing high-energy short-range (<100 µm) alpha particles to destroy surrounding tumor cells with minimal bone marrow toxicity.